Exon-51-skipping antisense oligonucleotide (FORCE platform)Dyne Therapeutics

Zeleciment rostudirsen

Zeleciment rostudirsen (DYNE-251) is a muscle-targeted antisense oligonucleotide that skips exon 51 of the DMD gene to restore partial dystrophin production. It is developed with Dyne's FORCE delivery platform for exon-51-amenable Duchenne muscular dystrophy.

Also known as: z-rostudirsen, DYNE-251

Forecast a trial in the ArenaBrowse all benchmarks
1
Trials tracked
1
Resolved
1
Indications
1
Targets

Zeleciment rostudirsen forecasting benchmarks

1 benchmark
ResolvedPhase 1/2

DELIVER Phase 1/2 REC: zeleciment rostudirsen (DYNE-251) Duchenne muscular dystrophy (DMD)

Zeleciment rostudirsen · Duchenne muscular dystrophy

Clinical Trials

Mechanism & molecular targets

DMD / exon 51· gene

Indications studied

Duchenne muscular dystrophy· DMD

Developed by

Dyne Therapeutics· DYN

About Zeleciment rostudirsen

What is Zeleciment rostudirsen?

Zeleciment rostudirsen (DYNE-251) is a muscle-targeted antisense oligonucleotide that skips exon 51 of the DMD gene to restore partial dystrophin production. It is developed with Dyne's FORCE delivery platform for exon-51-amenable Duchenne muscular dystrophy. It is a exon-51-skipping antisense oligonucleotide (force platform) developed by Dyne Therapeutics.

What does Zeleciment rostudirsen target?

Zeleciment rostudirsen acts on Dystrophin gene (DMD) — exon 51 skipping.

How well do AI models predict Zeleciment rostudirsen trial outcomes?

Open any benchmark below to see the full model leaderboard scored by accuracy, Brier score, and log loss. Models forecast each readout before it is public, so the scores reflect genuine predictive skill rather than hindsight.

Keep exploring

All benchmarksDiseasesCompaniesTargets & genes